

# Contents of *The American Journal of Psychiatry*

January 1996

Volume 153

## Editorials

- The State of the *Journal*. *N.C.A.* 1  
Seed or soil: how does our garden grow? *Leon Eisenberg* 3

## Images in Neuroscience

- Neuroimaging, IV: PET and the [<sup>15</sup>O]H<sub>2</sub>O technique, part 2: choosing a significance threshold. *Essay by N.C.A.* 6

## Special Article

- Money matters: a meta-analytic review of the effects of financial incentives on recovery after closed-head injury. *Laurence M. Binder and Martin L. Rohling* 7

## Regular Articles

- Parenting: a genetic-epidemiologic perspective. *Kenneth S. Kendler* 11

- Antecedents and consequences of negative life events in adulthood: a longitudinal study. *Xing-jia Cui and George E. Vaillant* 21

- Homosexuality in men and number of older brothers. *Ray Blanchard and Anthony F. Bogaert* 27

- Visual cortical dysfunction in Alzheimer's disease evaluated with a temporally graded "stress test" during PET. *Marc J. Mentis, Barry Horwitz, Cheryl L. Grady, Gene E. Alexander, John W. VanMeter, José M. Maisog, Pietro Pietrini, Mark B. Schapiro and Stanley I. Rapoport* 32

- Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. *Henry H. Holcomb, Nicola G. Cascella, Gunvant K. Thaker, Deborah R. Medoff, Robert F. Dannals and Carol A. Tamminga* 41

- Superior temporal gyrus volume in schizophrenia: a study using MRI morphometry assisted by surface rendering. *Jennifer J. Kulynych, Katalin Vadar, Douglas W. Jones and Daniel R. Weinberger* 50

- Psychodynamics and psychiatric diagnoses in pseudoseizure subjects. *Elizabeth S. Bowman and Omkar N. Markand* 57

- Exaggerated acoustic startle reflex in Gulf War veterans with posttraumatic stress disorder. *Charles A. Morgan III, Christian Grillon, Steven M. Southwick, Michael Davis and Dennis S. Charney* 64

- Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. *James L. Abelson and George C. Curtis* 69

- Anorexia nervosa and bulimia nervosa in alcohol-dependent men and women and their relatives. *Marc A. Schuckit, Jayson E. Tipp, Robert M. Anthenelli, Kathleen K. Bucholz, Victor M. Hesselbrock and John I. Nurnberger, Jr.* 74

- Serotonergic and noradrenergic dysregulation in alcoholism: *m*-chlorophenylpiperazine and Yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. *John H. Krystal, Elizabeth Webb, Ned L. Cooney, Henry R. Kranzler, Steven W. Southwick, George R. Heninger and Dennis S. Charney* 83

- Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. *Isabella J. E. Heuser, Ulrich Schweiger, Ulrike Gotthardt, Jürgen Schmider, Claas-H. Lammers, Michael Dettling, A. Yassouridis and Florian Holsboer* 93

## Clinical Case Conference

- Lifetime perturbations of bipolar disorder. *Dan G. Blazer* 100

## Images in Psychiatry

- Jean Etienne Dominique Esquirol, 1772–1840. *Essay by Pierre Pichot* 103

## Brief Reports

- The Thalamus as a site of action of antipsychotic drugs. *Bruce M. Cohen and Weihua Wan* 104

- Linkage study of the D<sub>5</sub> dopamine receptor gene (DRD5) in multiplex Icelandic and English schizophrenia pedigrees. *Gursharan Kalsi, Robin Sherrington, Baljinder S. Mankoo, Jon Brynjolfsson, Thordur Sigmundsson, David Curtis, Tim Read, Patrice Murphy, Robert Butler, Hannes Petursson and Hugh M. D. Gurling* 107

- Prevalence of panic in patients referred for pulmonary function testing at a major medical center. *Mark H. Pollack, Richard Kradin, Michael W. Otto, John Worthington, Robert Gould, Susan A. Sabatino and Jerrold F. Rosenbaum* 110

- Elevated plasma levels of neuropeptide Y in patients with panic disorder. *Jean-Philippe Boulenger, Ilona Jerabek, François B. Jolicœur, Yvon-Jacques Lavallée, Richard Leduc and Alain Cadieux* 114

- Prevalence of borderline personality symptoms in two groups of obese subjects. *Randy A. Sansone, Lori A. Sansone and David W. Morris* 117

- Pathological gambling and platelet MAO activity: a psychobiological study. *Carlos Blanco, Luis Orensanz-Muñoz, Carmen Blanco-Jerez and Jerónimo Saiz-Ruiz* 119



## CONSULTANT PSYCHIATRIST

Mental Health Services at Eastbay Health provide, to a population of approximately 50,000, integrated services addressing both personal health and disability support needs through acute inpatient care (exclusive of high risk/IPC), community based services, outpatient clinics, and liaison psychiatry.

The position provides an opportunity to work with an experienced team and service which has received additional revenue to ensure growth of community services.

The Eastern Bay of Plenty is an attractive coastal area; has a very pleasant climate; and offers a range of outdoor and cultural pursuits.

This is a permanent position; however locum or short term employment options would be considered.

For further information contact:


The Personnel Officer  
Eastbay Health  
PO Box 241, Whakatane  
NEW ZEALAND  
Telephone 64 7 307 8999  
or Fax 64 7 307 0451

### Epilim Oral Prescribing Information

**Presentation** Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*: the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*: initially 400mg a day increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*: initially 20mg/kg/day - the dose may be increased in steps to a maximum of 40mg/kg/day provided that plasma levels are monitored. Epilim Chrono may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**: levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** **Contraindications** Active liver disease, family history of severe liver disease, hypersensitivity to valproate. **Side effects** Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being monitored on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address**: Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone**: (01483) 505515 **Fax**: (01483) 35432. Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation** August 1995.

### References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994, **57**: 264-277
2. Gilham R.A., *Epilepsy Res.* 1990, **7**: 219-225



NOW  
ONCE-DAILY

# Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,<sup>1</sup> it is well tolerated (particularly with regard to cognitive function)<sup>2</sup>, and offers patients the convenience of once-daily dosing.


It helps people with epilepsy get on with their lives today, and look forward to tomorrow.



**Epilim** **CHRONO**  
Sodium Valproate Ph. Eur. Controlled Release  
Valproic Acid Fr.P

Once-daily management  
for all forms of epilepsy

Leadership isn't given. It's earned.



**PROZAC**  
*fluoxetine*

The World's No. 1  
prescribed  
antidepressant brand

Further information is available on request from:  
Dista Products Limited, Dextra Court, Chapel Hill  
Basingstoke, Hampshire RG21 5SY.

Legal Category: POM.

'PROZAC' is a Dista trade mark.

Date of preparation: August 1995



PZ68